Kararlı Anjina Pektorisli Hastalarda Trimetazidin Tedavisinin Lipoprotein İlişkili Fosfolipaz A2 Düzeyi ve Egzersiz Parametreleri Üzerine Etkisi

Year 2015, Volume: 18 Issue: 3, 126 - 129, 01.12.2015

Cem Bostan , Erdem Karacop Cüneyt Koçaş Okay Abacı Ayşem Kaya Zerrin Yiğit

Abstract

Giriş:
Kararlı anjina pektorisli hastalarda, metabolik bir
anti-iskemik ilaç olan trimetazidin (TMZ) tedavisinin risk faktörü olarak kabul
edilen lipoprotein ilişkili fosfolipaz A₂ (Lp-PLA₂) düzeyi ve egzersiz parametreleri üzerine etkisi
araştırıldı.

Hastalar
ve Yöntem: Egzersiz testi pozitif olan
kararlı anjina pektorisli 30 hasta (ort. yaş 62.1 ± 8.3; dağılım 47-77)
çalışmaya alındı. Trimetazidin tedavisi öncesinde Lp-PLA₂ düzeyleri ölçüldü; 12 haftalık TMZ tedavisi sonrasında
egzersiz testi ve Lp-PLA₂ ölçümleri tekrarlandı.

Bulgular:
Trimetazidin tedavisi sonrasında Lp-PLA₂ düzeyleri anlamlı düşüş (p= 0.006), egzersiz iş yükü
anlamlı artış (p= 0.048) gösterdi.

Sonuç: Trimetazidin tedavisi kardiyak
metabolizma değişikliği sonucu serbest oksijen radikal oluşumunu ve
enflamasyonu azaltarak Lp-PLA₂
düzeyinde anlamlı düşüş sağlamaktadır. Bu bulgu, egzersiz parametrelerindeki
iyileşmelerle birlikte, TMZ tedavisinin kararlı anjina pektorisli hastaların
prognozunda olumlu katkı sağlayabileceğini göstermektedir.

Keywords

Anjina, kararlı, trimetazidin, lipoprotein ilişkili fosfolipaz A2

Effects of Trimetazidine Treatment on the Lipoprotein-Associated Phospholipase A2 Level and Exercise Parameters in Patients with Stable Angina Pectoris

Abstract

Introduction:
We examined the clinical effectiveness of trimetazidine
(TMZ), a metabolic anti-ischemic agent, on lipoprotein-associated phospholipase
A₂ (Lp-PLA₂) levels, which is considered a risk factor
for cardiovascular events, and on exercise parameters in patients with stable
angina pectoris (SAP).

Patients
and Methods: The study included 30 patients (mean age 62.1
± 8.3 years; range 47 to 77 years) with SAP and a positive exercise test
result. Serum Lp-PLA₂ levels were measured at baseline. Exercise
testing and Lp-PLA₂ measurements were repeated after at least 12
weeks of TMZ treatment.

Results: After
TMZ treatment, Lp-PLA₂ levels decreased significantly (p= 0.006),
and workload increased significantly (p= 0.048).

Conclusion:
Trimetazidine treatment reduces serum Lp-PLA₂
levels via shifting cardiac metabolism, resulting in decreased production of
free oxygen radicals and inflammation. This finding, together with improvements
in exercise test parameters, suggests that TMZ may have a beneficial effect on
the prognosis of patients with SAP.

Keywords

Angina, stable, trimetazidine, lipoprotein-associated phospholipase A2

References

• 1. Hu B, Li W, Xu T, Chen T, Guo J. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. Clin Cardiol 2011;34:395-400.
• 2. Epps KC, Wilensky RL. Lp-PLA2-a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 2011;269:94-106.
• 3. Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J 2011;2:27-38.
• 4. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-31.
• 5. Siama K, Tousoulis D, Papageorgiou N, Siasos G, Tsiamis E, Bakogiannis C, et al. Stable angina pectoris: current medical treatment. Curr Pharm Des 2013;19:1569-80.
• 6. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81.
• 7. Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC. Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol 2006;98(5A):19J-24J.
• 8. Maridonneau-Parini I, Harpey C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985;20:148-51.
• 9. Park KH, Park WJ, Kim MK, Park DW, Park JH, Kim HS, et al. Effects of trimetazidine on endothelial dysfunction after sheath injury of radial artery. Am J Cardiol 2010;105:1723-7.
• 10. Zhou X, Li C, Xu W, Chen J. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One 2012;7:e40424.
• 11. Kuralay F, Altekin E, Yazlar AS, Onvural B, Goldeli O. Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine. Tohoku J Exp Med 2006;208:203-12.
• 12. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
• 13. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein- associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008;101:41F-50F.
• 14. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26:1586-93.
• 15. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006;26:2517-22.
• 16. Sabatine MS, Morrow DA, O’Donoghue M, Jablonksi KA, Rice MM, Solomon S, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27:2463-9.
• 17. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
• 18. Güler N, Eryonucu B, Güneş A, Güntekin U, Tuncer M, Özbek H. Effects of trimetazidine on submaximal exercise test in patients with acute myocardial infarction. Cardiovasc Drugs Ther 2003;17:371-4.
• 19. Koylan N, Bilge AK, Adalet K, Mercanoğlu F, Büyüköztürk K, TTS Group. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS). Acta Cardiol 2004;59:644-50.